In preclinical studies, CDCP1-targeted therapies, including ADCs, radiolabeled antibodies, and bispecific T-cell engagers, have suppressed tumor growth in PDAC and other solid tumors [7, 8, 35]. This evidence concerns the gene CDCP1 and neoplasm.